Avacincaptad pegol reduces geographic atrophy growth rate at 18 months
The phase 2/3 GATHER1 trial showed patients with geographic atrophy due to age-related macular degeneration who received avacincaptad pegol experienced a 28% reduction in rate of geographic atrophy growth over 18 months.
Donald J. D’Amico, MD, presented the results at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
“The GATHER1 study achieved the primary efficacy endpoint for reduction in the growth rate of geographic atrophy for both the 2 mg and 4 mg doses of avacincaptad vs. sham,” he said.
The trial was implemented in two parts. Patients with geographic atrophy due to AMD were treated with Zimura (avacincaptad pegol, Iveric bio), a potent inhibitor of complement C5, or sham. Part 1 of the trial included patients receiving either 2 mg or 1 mg doses of avacincaptad pegol compared with patients receiving sham injections over 18 months. Part 2 included patients receiving either 2 mg or 4 mg doses of avacincaptad pegol compared with sham injections over 18 months, D’Amico said.
At 18 months, patients receiving 2 mg doses of avacincaptad pegol experienced a 28% reduction in geographic atrophy growth rates compared with sham. Patients receiving 4 mg doses experienced a 30% reduction in geographic atrophy growth rates compared with sham.
The mean change in best corrected visual acuity and low luminance best corrected visual acuity from baseline to months 12 and 18 was not significantly different in treated subjects compared with sham subjects, he said.
The GATHER2 trial, a confirmatory pivotal clinical trial comparing patients receiving 2 mg of avacincaptad pegol compared with sham, is currently enrolling.
Collapse
D’Amico DJ. Avacincaptad pegol, a novel C5 inhibitor, significantly reduces the mean rate of geographic atrophy growth in the phase 2/3 GATHER1 clinical trial. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting)
Read more about